TaleNeprilysin and Neprilysin inhibition in chronic kidney disease

TaleNeprilysin and Neprilysin inhibition in chronic kidney disease

<p><strong>Purpose of review </strong></p> Chronic kidney disease (CKD) is associated with increased risk of progression to end-stage kidney disease and cardiovascular events. There is limited evidence that available treatments have beneficial effects on cardiorenal outcomes...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Judge, PK, Haynes, R
Format:	Journal article
Język:	English
Wydane:	Lippincott, Williams & Wilkins 2021

Podobne zapisy

Neprilysin inhibition in chronic kidney disease.
od: Judge, P, i wsp.
Wydane: (2014)

Chronic kidney disease, heart failure and neprilysin inhibition
od: Haynes, R, i wsp.
Wydane: (2019)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
od: Kawa Dizaye, i wsp.
Wydane: (2019-05-01)

Neprilysin Inhibitors and Bradykinin
od: Duncan J. Campbell, i wsp.
Wydane: (2018-09-01)

2003 Mixed meal effects of neprilysin inhibition
od: Jessica R. Wilson, i wsp.
Wydane: (2018-06-01)

Angiotensin Receptor-Neprilysin Inhibitor for Chronic Kidney Disease: Strategies for Renal Protection
od: Erika Hishida, i wsp.
Wydane: (2024-10-01)

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
od: In-Jeong Cho, i wsp.
Wydane: (2021-12-01)

Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.
od: Matthew Burrell, i wsp.
Wydane: (2016-01-01)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
od: Nathalie Esser, i wsp.
Wydane: (2022-06-01)

Application of Angiotensin Receptor–Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus
od: Liangying Gan, i wsp.
Wydane: (2022-07-01)

Neprilysin as a Biomarker: Challenges and Opportunities
od: Noemi Pavo, i wsp.
Wydane: (2020-08-01)

Relevance of Neutrophil Neprilysin in Heart Failure
od: Suriya Prausmüller, i wsp.
Wydane: (2021-10-01)

Urinary neprilysin in the critically ill patient
od: Sahra Pajenda, i wsp.
Wydane: (2017-05-01)

The role of neprilysin in regulating the hair cycle.
od: Naoko Morisaki, i wsp.
Wydane: (2013-01-01)

Serum neprilysin levels are elevated in preeclampsia
od: Nevin Tüten, i wsp.
Wydane: (2021-09-01)

Roles of Natriuretic Peptides and the Significance of Neprilysin in Cardiovascular Diseases
od: Hitoshi Nakagawa, i wsp.
Wydane: (2022-07-01)

Urinary neprilysin – Another marker to predict postoperative acute kidney injury
od: Abhijit Nair, i wsp.
Wydane: (2023-01-01)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
od: A.S. Ryazanov, i wsp.
Wydane: (2023-04-01)

Soluble neprilysin and survival in critically ill patients
od: Max Lenz, i wsp.
Wydane: (2022-04-01)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
od: Frederik H. Verbrugge, i wsp.
Wydane: (2020-07-01)

Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?
od: Sverre E. Kjeldsen, i wsp.
Wydane: (2019-03-01)

Angiotensin Receptor‐Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension
od: Danial Sharifi Kia, i wsp.
Wydane: (2020-07-01)

Breakthrough in Heart Failure therapy: LCZ696 combining ACE-Neprilysin inhibition
od: Sandeep Lahiry
Wydane: (2017-01-01)

Adipolin, Chemerin, Neprilysin and Metabolic Disorders Associated with Obesity
od: Marcelina Sperling, i wsp.
Wydane: (2023-07-01)

Active site mutations change the cleavage specificity of neprilysin.
od: Travis Sexton, i wsp.
Wydane: (2012-01-01)

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure
od: Julio Núñez, i wsp.
Wydane: (2017-08-01)

Inhibition of neprilysin with sacubitril without RAS blockage aggravates renal disease in Dahl SS rats
od: Iuliia Polina, i wsp.
Wydane: (2021-01-01)

Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF
od: Suriya Prausmüller, i wsp.
Wydane: (2020-06-01)

The Association between Neprilysin gene polymorphisms and Alzheimer’s disease in Tibetan population
od: Siwei Chen, i wsp.
Wydane: (2021-03-01)

Brain Shuttle Neprilysin reduces central Amyloid-β levels.
od: Christopher R Campos, i wsp.
Wydane: (2020-01-01)

Elevated neprilysin in placental vesicles derived from preeclamptic pregnancies
od: Gill, M, i wsp.
Wydane: (2018)

The effect of neprilysin and renin inhibition on the renal dysfunction following ischemia‐reperfusion injury in the rat
od: Fayez T. Hammad, i wsp.
Wydane: (2021-03-01)

Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease
od: Yogesh N. V. Reddy, i wsp.
Wydane: (2019-08-01)

Angiotensin-Neprilysin Inhibitor Therapy: A Retrospective Chart Study
od: Roda Plakogiannis, i wsp.
Wydane: (2025-02-01)

Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
od: Kangbo Li, i wsp.
Wydane: (2023-02-01)

Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy.
od: Miners, J, i wsp.
Wydane: (2006)

Amyloid beta and Alzheimer’s Disease: The role of neprilysin-2 in amyloid-beta clearance
od: Robert eMarr, i wsp.
Wydane: (2014-08-01)

Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer's disease.
od: Carl I Webster, i wsp.
Wydane: (2014-01-01)

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
od: Rolf Wachter, i wsp.
Wydane: (2020-06-01)

Updates for Cardio‐Kidney Protective Effects by Angiotensin Receptor‐Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection
od: Shunichiro Tsukamoto, i wsp.
Wydane: (2023-04-01)